Achievement of pre-clinical milestone triggers $4M payment from GSK to Epizyme Epizyme.

For each target in the collaboration, Epizyme will lead to research up to advancement candidate selection primarily, and GSK will be responsible for advancement and commercialization solely.. Achievement of pre-clinical milestone triggers $4M payment from GSK to Epizyme Epizyme, Inc., a company leading the discovery and development of customized therapeutics for genetically-described cancer patients, today announced the achievement of pre-scientific milestones in it is alliance with GlaxoSmithKline , triggering $4 million in milestone payments.As announced previously, Abbott commenced the tender present on Jan. 27, 2009, for every one of the outstanding shares of AMO common share for $22 per talk about in money. The tender present was produced pursuant to an Provide to Purchase, dated Jan. 27, 2009, and regarding the the Plan and Agreement of Merger, dated Jan. 11, 2009, entered into by and among Abbott, Rainforest Acquisition Inc., a owned subsidiary of Abbott wholly, and AMO, which Abbott and AMO announced on Jan. 12, 2009.

91 percent of Us citizens know genetic details has important utility in managing health 23andMe, the leading personal genetics business, is celebrating National DNA Day time by taking an in-depth appearance at what Americans know about their DNA and how genetics are likely involved in our everyday lives.